TFAP2A regulates nasopharyngeal carcinoma growth and survival by targeting HIF-1a signaling pathway

Cancer Prevention Research

Volumn 7, Issue 2, 2014, Pages 266-277

  Shi, Dingbo ^a   Xie, Fangyun ^a   Zhang, Yun ^a   Tian, Yun ^a   Chen, Wangbing ^a   Fu, Lingyi ^a   Wang, Jingshu ^a   Guo, Wei ^c   Kang, Tiebang ^a   Huang, Wenlin ^a,b   Deng, Wuguo ^a,b,c  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Guangzhou Double Bioproduct Inc   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-2; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84893832243     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0271     Document Type: Article

References (44)

1. Brennan B. Nasopharyngeal carcinoma. Orphanet J Rare Dis 2006; 26:23.
2. Sen S. Aneuploidy and cancer. Curr Opin Oncol 2000;12:82-8.
3. Desalvo MN. Radiation necrosis of the pons after radiotherapy for nasopharyngeal carcinoma: diagnosis and treatment. J Radiol Case Rep 2012;6:9-16.
4. Zhao Z, Lan Y, Bai S, Shen J, Xiao S, Lv R, et al. Late-onset radiation induced optic neuropathy after radiotherapy for nasopharyngeal carcinoma. J Clin Neurosci 2013;20:702-6.
5. Wan XB, Zhao Y, Fan XJ, Cai HM, Zhang Y, Chen MY, et al. Molecular prognostic prediction for locally advanced nasopharyngeal carcinoma by support vector machine integrated approach. PLoS One 2012;7: e31989.
6. Motley AM, Berg N, Taylor MJ, Sahlender DA, Hirst J, Owen DJ, et al. Functional analysis of AP-2α and mu2 subunits. Mol Biol Cell 2006;17: 5298-308.
7. Pellikainen J, Kataja V, Ropponen K, Kellokoski J, Pietiläinen T, Böhm J, et al. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer. Clin Cancer Res 2002;8: 3487-95.
8. Ropponen KM, Kellokoski JK, Pirinen RT, Moisio KI, Eskelinen MJ, Alhava EM, et al. Expression of transcription factor AP-2 in colorectal adenomas and adenocarcinomas comparison of immunohistochemistry and in situ hybridisation. J Clin Pathol 2001;54:533-8.
9. Eckert D, Buhl S, Weber S, Jäger R, Schorle H. The AP-2 family of transcription factors. Genome Biol 2005;6:246.
10. Cheng C, Ying K, Xu M, Zhao W, Zhou Z, Huang Y, et al. Cloning and characterization of a novel human transcription factor AP-2β like gene (TFAP2BL1). Int J Biochem Cell Biol 2002;34:78-86.
11. Zhao F, Satoda M, Licht JD, Hayashizaki Y, Gelb BD. Cloning and characterization of a novel mouse AP-2 transcription factor, AP-2δ, with unique DNA binding and transactivation properties.J Biol Chem 2001;276:40755-60.
12. Feng W, Williams T. Cloning and characterization of the mouse AP-2ε gene: a novel family member expressed in the developing olfactory bulb. Mol Cell Neurosci 2003;24:460-75.
13. Wang HV, Vaupel K, Buettner R, Bosserhoff AK, Moser M. Identification and embryonic expression of a new AP-2 transcription factor, AP-2ε. Dev Dyn 2004;231:128-35.
14. Hilger-Eversheim K, Moser M, Schorle H, Buettner R. Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene 2000;260:1-12.
15. Werling U, Schorle H. Transcription factor gene AP-2γ essential for early murine development. Mol Cell Biol 2002;22:3149-56
16. Wu F, Lee AS. YY1 as a regulator of replication-dependent hamster histone H3.2 promoter and an interactive partner of AP-2. J Biol Chem 2001;276:28-34.
17. McPherson LA, Loktev AV, Weigel RJ. Tumor suppressor activity of AP-2α mediated through a direct interaction with p53. J Biol Chem 2002;277:45028-33.
18. Batsché E,Muchardt C, Behrens J, Hurst HC, Crémisi C.RBand c-Myc activate expression of the E-cadherin gene in epithelial cells through interaction with transcription factor AP-2. Mol Cell Biol 1998;18: 3647-58.
19. Aqeilan RI, Palamarchuk A, Weigel RJ, Herrero JJ, Pekarsky Y, Croce CM. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2γ transcription factor. Cancer Res 2004;64:8256-61.
20. Bragança J, Eloranta JJ, Bamforth SD, Ibbitt JC, Hurst HC, Bhattacharya S. Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2. J Biol Chem 2003;278:16021-9.
21. Karjalainen JM, Kellokoski JK, Eskelinen MJ, Alhava EM, Kosma VM. Down-regulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J Clin Oncol 1998;16: 3584-91.
22. Bar-Eli M. Role of AP-2 in tumor growth and metastasis of human melanoma. Cancer Metastasis Rev 1999;18:377-85.
23. Ruiz M, Pettaway C, Song R, Stoeltzing O, Ellis L, Bar-Eli M. Activator protein 2α inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Res 2004; 64:631-8.
24. Douglas DB, Akiyama Y, Carraway H, Belinsky SA, Esteller M, Gabrielson E, et al. Hyper-methylation of a small CpG uanine-rich region correlates with loss of activator protein-2a expression during progression of breast cancer. Cancer Res 2004;64:1611-20.
25. Anttila MA, Kellokoski JK, Moisio KI, Mitchell PJ, Saarikoski S, Syrjänen K, et al. Expression of transcription factor AP-2α predicts survival in epithelial ovarian cancer. Br J Cancer 2000;82:1974-83.
26. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, et al. Loss of the AP-2α transcription factor is associated with the grade of human gliomas. Clin Cancer Res 2005;11:267-72.
27. Wang W, Lv L, Pan K, Zhang Y, Zhao JJ, Chen JG, et al. Reduced expression of transcription factor AP-2α is associated with gastric adenocarcinoma prognosis. PLoS One 2011;6:e24897.
28. Schwartz B, Melnikova VO, Tellez C, Mourad-Zeidan A, Blehm K, Zhao YJ, et al. Loss of AP-2α results in deregulation of E-cadherin andMMP-9 and an increase in tumorigenicity of colon cancer cells in vivo. Oncogene 2007;26:4049-58.
29. Nordentoft I, Dyrskjøt L, Bødker JS, Wild PJ, Hartmann A, Bertz S, et al. Increased expression of transcription factor TFAP2α correlates with chemo-sensitivity in advanced bladder cancer. BMC Cancer 2011; 11:135.
30. Sumigama S, Ito T, Kajiyama H, Shibata K, Tamakoshi K, Kikkawa F, et al. Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by over-expression of AP-2a. Oncogene 2004;23: 5496-504.
31. Kaluz S, Kaluzová M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor-and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 2009;1795:162-72.
32. López-Lázaro M. Role of oxygen in cancer: looking beyond hypoxia. Anticancer Agents Med Chem 2009;9:517-25.
33. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13.
34. Cheeseman MT, Tyrer HE, Williams D, Hough TA, Pathak P, Romero MR, et al. HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants. PLoS Genet 2011;7:e1002336.
35. Rathinavelu A, Narasimhan M, Muthumani P. A novel regulation of VEGF expression by HIF-1a and STAT3 in HDM2 transfected prostate cancer cells. J Cell Mol Med 2012;16:1750-7.
36. Falk T, Congrove NR, Zhang S, McCourt AD, Sherman SJ, McKay BS. PEDF and VEGF-A output from human retinal pigment epithelial cells grown on novel micro-carriers. J Biomed Biotechnol 2012;2012: 278932.
37. Lombaert N, Castrucci E, Decordier I, Van Hummelen P, Kirsch-Volders M, Cundari E, et al. Hard-metal (WC-Co) particles trigger a signaling cascade involving p38 MAPK, HIF-1α, HMOX1, and p53 activation in human PBMC. Arch Toxicol 2013;87:259-68.
38. Tung KH, Lin CW, Kuo CC, Li LT, Kuo YH, Lin CW, et al.CHCpromotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling. Cancer Lett 2013;331:58-67.
39. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA, et al. Epidermal growth factor and hypoxia-induced expression of CXCchemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/ mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1a. J Biol Chem 2005;280:22473-81.
40. Rapisarda A, Melillo G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res 2012;114:237-67.
41. Ahluwalia A, Tarnawski AS. Critical role of hypoxia sensor-HIF-1α in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr Med Chem 2012;19:90-7.
42. Thomas AL, Morgan B, Drevs J,Unger C, Wiedenmann B, Vanhoefer U, et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 2003;30:32-8.
43. Lai LJ, Ho TC. Pigment epithelial-derived factor inhibits c-FLIP expression and assists ciglitazone induced apoptosis in hepatocellular carcinoma. Anticancer Res 2011;31:1173-80.
44. Hoshina D, Abe R, Yamagishi SI, Shimizu H. The role of PEDF in tumor growth and metastasis. Curr Mol Med 2010;10:292-5.